drugset
drugset / Trial / NCT05177237

Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma

NCT05177237 ↗

Phase 2 Unknown 30 enrolled Jiangxi Provincial Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the effectiveness and safety of Endostar combined with corticosteroids on Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma patients. detailed description:

Timeline

Start
2021-07-28
Primary completion
2024-12-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic 210 mg Other
Background Methylprednisolone Other / unclassified 10 mg Intravenous

Indications

nasopharyngeal carcinoma